Alvotech announces successful closure of FDA inspection of manufacturing facility
Rhea-AI Summary
Alvotech (NASDAQ: ALVO; ALVO-SDB) announced that the U.S. FDA has closed its May 2026 inspection of the company’s manufacturing facility in Reykjavik, Iceland, and confirmed the site’s inspection classification as Voluntary Action Indicated (VAI).
According to Alvotech, the outcome reflects work to strengthen quality systems and manufacturing operations, and management believes actions taken have addressed the observations identified during the inspection. The company continues to work with the FDA to advance recent Biologics License Applications (BLAs) toward approval.
Alvotech recently resubmitted BLAs for AVT05 (biosimilar to Simponi) and AVT06 (biosimilar to Eylea), and the FDA accepted a BLA submission for AVT16 (proposed biosimilar to Entyvio) in June 2026. Alvotech reports five biosimilars already approved and marketed in multiple global markets and a pipeline of 13 disclosed biosimilar candidates across autoimmune, eye, bone, respiratory and oncology indications.
Positive
- FDA inspection closed for Reykjavik facility with VAI classification in May 2026
- BLAs resubmitted for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar)
- FDA accepted June 2026 BLA submission for AVT16 (proposed Entyvio biosimilar)
- Five biosimilars already approved and marketed in multiple global markets
- Pipeline of 13 disclosed biosimilar candidates across several major disease areas
Negative
- None.
Market reaction after FDA inspection closure: ALVO +13.87% in the Jul 29 session
In the Jul 29 session, ALVO gained 13.87%, reflecting a significant positive market reaction. Argus tracked a peak move of +11.6% during that session. Our momentum scanner triggered 38 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.7x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 03 | Share pledge disclosure | Neutral | -4.2% | Manager-related filings disclosed pledges involving Alvotech shares and depository receipts. |
| Jul 01 | Term loan facility | Positive | -3.0% | Alvotech secured a $75 million term loan facility with 12.50% cash interest. |
| Jun 22 | Share acquisition | Positive | +1.4% | Celtic Lux Holdings acquired 10,133,333 Alvotech shares at $3.75. |
| Jun 18 | Offering closing | Negative | +0.1% | Public offering and private placement closed for expected aggregate gross proceeds of $165 million. |
| Jun 18 | Proposed offering | Negative | +0.1% | Proposed public offering and concurrent private placement targeted approximately $125 million. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions diverged from the apparent announcement direction in four of five events; the only aligned event involved a share acquisition.
Key Terms
voluntary action indicated regulatory
biologics license applications regulatory
biosimilar medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has closed its inspection of the company’s manufacturing facility in Reykjavik, Iceland, conducted in May 2026. The FDA has confirmed the inspection classification of the manufacturing site is Voluntary Action Indicated (VAI).
“This is an important milestone for Alvotech and reflects the significant work our teams have undertaken to further strengthen our quality systems and manufacturing operations,” said Lisa Graver, CEO of Alvotech. “With the conclusion of the FDA’s recent inspection, we are confident that the actions we have taken have effectively addressed the observations identified. We continue to work with the FDA to advance our recent Biologics Licence Applications towards approval.”
Alvotech continues to advance its pipeline of biosimilar candidates. The company recently announced the resubmission of Biologics License Applications (BLAs) for AVT05, Alvotech’s biosimilar to Simponi® (golimumab), and AVT06, Alvotech’s biosimilar to Eylea® (aflibercept), and the acceptance by the FDA of the submission of a BLA for AVT16, Alvotech’s proposed biosimilar to Entyvio® (vedolizumab) to the FDA in June 2026.
Alvotech continues to work closely with health authorities worldwide to bring high-quality, affordable biologic medicines to patients.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad (US)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes 13 disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China and other Asian countries, and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.
None of the information on the Alvotech website shall be deemed part of this press release.
Use of trademarks
Simponi® and Simponi Aria® are trademarks of Johnson & Johnson. Eylea® is a trademark of Regeneron Pharmaceuticals Inc. Entyvio® is a registered trademark of Millennium Pharmaceuticals, Inc.
